Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | MURANO: safety and efficacy data presented at ASH 2017

Jennifer Brown • 9 Dec 2017
ASH 2017
Chronic Lymphocytic Leukemia Ibrutinib Venetoclax
MURANO

Venetoclax is a Bcl-2 inhibitor approved in USA for CLL patients with 17p deletion, and in Europe for those who failed or do not tolerate BCR inhibitors. Here, Jennifer Brown, MD, PhD from Dana-Farber Cancer Institute, Boston, MA discusses the results presented at ASH 2017 on the MURANO trial, where venetoclax has been tested in combination with rituximab versus bendamustine plus rituximab. This video was recorded at the American Society of Hematology Annual Meeting 2017, held in Atlanta, GA.

More from Jennifer Brown

1:18
Investigating acquired mutations in patients with R/R CLL who progressed in the ALPINE study
Jennifer Brown • 11 Dec 2023
1:55
Genomic evolution of patients with CLL who progress on pirtobrutinib in the BRUIN trial
Jennifer Brown • 11 Dec 2023
1:43
Extended follow-up of the ALPINE trial: superior outcomes with zanubrutinib in R/R CLL/SLL
Jennifer Brown • 11 Dec 2023
1:24
Sequencing of BTK inhibitors in CLL
Jennifer Brown • 6 Sep 2023

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals